Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06591858

Evaluation of Renal Function in Patients With Hyperthyroidism

To evaluate the effect of subclinical and overt Hyperthyroidism in renal function

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

About this study

  • Thyroid disorders are very common with a high prevalence among the general population. Thyroid diseases are associated with many detrimental effects that have a serious impact on various body systems.(1)
  • Hyperthyroidism can be overt or subclinical. Overt hyperthyroidism is defined as low serum thyroid stimulating hormone (TSH) and elevated serum thyroxin (T4), tri-iodothyronine (T3), or both. Whereas subclinical hyperthyroidism (SCH) is defined as low serum TSH level with normal serum levels of T3 and T4.(2)
  • The relationship between thyroid hormones and kidney function is well-known for many years. Thyroid diseases adversely affect renal physiology; meanwhile, kidney diseases could result in thyroid dysfunction.
  • Thyroid hormones contribute to the maintenance of water and electrolyte balance, and participate in the renal transport system. Hyperthyroidism results in an increased glomerular filtration rate (GFR) by about 18-25%. due to increased renal blood flow and activation of renin angiotensin-aldosterone system (RAAS). Also, these changes have been reported in patients with hyperthyroidism.(3-5)
  • Several mechanisms were found playing roles on increasing both the size and functional capacity of kidney:
  • Thyroid hormone directly influences the expression and activity of most of renal transporters by direct binding of thyroid hormone to the promoter region of a transporter gene (6)
  • In hyperthyroid state beta-adrenergic receptors in kidney cortex, and synthesis and secretion of renin by juxtaglomerular cells are increased, which in turn enhance angiotensin-converting enzyme activity.(7)
  • Increased RAAS activity results in afferent arteriolar vasodilatation and efferent arteriolar vasoconstriction with a consequent increase in the filtration pressure...(8) D) Hyperthyroidism increases systolic blood pressure by increasing heart rate, decreasing systemic vascular resistance, raising cardiac output, and increases nitric oxide production which all contributes to the hyper dynamic circulation. Hyperthyroidism results in increased renal blood flow.(7)
  • Observed that both BUN and creatinine levels increased significantly after euthyroidism was achieved in hyperthyroid patients, these findings point out to true decline in renal function rather than a mere adaptation to hemodynamic changes.

Although the mechanistic link between thyroid and kidney disease remains unclear, hyperthyroidism may have significant effect on renal function

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged (18_80 years) diagnosed subclinical and overt Hyperthyroidism with overt Hyperthyroidism

Exclusion criteria

  • Patients with D.M
  • Patients with Hypertension
  • Patients with CKD or ESRD
  • IHD
  • Pateints receiving medication known to affect renal function as contrast agent, non-steroidal anti-inflammatory drugs and ACEIs

Treatment and study plan

Primary outcomes

  1. Evaluation of renal function in patients with subclinical and overt Hyperthyroidism.

    Time frame: baseline

Study contacts

Contact information is provided by the study sponsor or research team.

Ahmed K Abdelghaney

CONTACT

[email protected]

201093375923

Hanaa M Riad

CONTACT

[email protected]

+201094608083

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

Evaluation of Renal Function in Patients With Subclinical and Overt Hyperthyroidism

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Sep 19, 2024
Registry last updated
Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.